23rd Orphan Drugs & Rare Diseases Global Congress 2025

Addressing the challenges in drug development, treatment availability, and access.

  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Co-located with the 8th EXPANDED ACCESS PROGRAMMES WORLD Congress 2025 Europe 

Orphan Drugs & Rare Diseases Global Congress 2025 Europe

Addressing the challenges in drug development, treatment availability, and access.

FACILITATE LIVE is proud to present our Orphan Drugs and Rare Diseases Global Congress 2025 Europe. It’s the 23rd in the series of our Flagship Orphan Drugs & Rare Diseases events. This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

An estimated 300 million people live with rare disease globally, an estimated 36 million in Europe. 80% of rare diseases have a genetic cause, almost 70% of which present in childhood. Collectively, people living with a rare disease represent one of the largest underserved patient communities in the world, with only 5% of known rare diseases having one or more approved treatments. The average time for an accurate diagnosis takes 4·8 years; and about 30% of children with a rare disease die before the age of 5 years. The complex biology and lack of understanding of the natural history of rare diseases makes drug, biologic, and device development in rare diseases very challenging. However, there is limited medical expertise and knowledge about rare diseases, and fewer than 1,000 diseases have even minimal scientific knowledge. Accurate diagnosis and treatment for these diseases has also been teeming with regulatory and logistical barriers. There is an urgent need for a regulatory framework that encourages safe therapeutic innovations and helps ensure their timely access to patients.

According to reports, the global Orphan Drugs Market size has reached a value of USD 214.8 Billion in 2023. looking forward, the market is projected to reach USD 541.3 Billion in 2032, at a CAGR of 1o.5% during the forecast period, 2024-2032. This growth has been driven by several factors such as increasing prevalence of rare diseases exhibited by the growing number of people affected by Rare diseases and rare cancer. Supportive government regulations and policies also helps to drive the market. Increasing R&D initiatives and investments by prominent players and patient advocacy involvement have resulted in major pharmaceutical breakthroughs. The development of blockbuster drugs for the treatment of several rare diseases and advances in genomics and personalised medicines will create opportunities and contribute exponentially to the overall market growth.

The two-day Congress will provide an interactive, cutting edge, and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts surrounding orphan drugs and rare diseases.

We look forward to meeting you at the Congress!

Sincerely yours,

Jocelyn Raguindin
Conference Director
Facilitate Live

GAIN LATEST INSIGHTS ON:

WHO SHOULD ATTEND?

This congress is specially created for valued stakeholders in the Rare Disease community:

Network with Presidents, Heads/Chiefs, VPs, Directors, and Managers in the area of:

speakers
0 +
days Congress
0
Presentation
0 +
Attendees
0 +

Key Industry Expert Speakers

PROF JAMES LEVINE

President

Sanford HeFondation Ipsenalth

Surabhi Verma

Chief Medical Officer

Leadiant Biosciences

Amanda Bok

Chief Strategy Officer

The Synergist

Sheela Upadhyaya,

Chair Elect, Rare Disease Special Interest Group

ISPOR

Nick Sireau

Chair & CEO

AKU Society

Guillaume Canaud

Translational Medicine & Targeted Therapies Unit

Necker Enfants Malades

LINDSAY RANDALL

Mother, Founder, CEO

Arthur’s Quest

Dr. Femida Gwadry-Sridhar

Founder and CEO

Pulse infoframe Inc.

Dan Lewi

Head of Business Development and Patient Advocacy

Pulse infoframe Inc., Co- founder, CATS Foundation

DR ALBERTO MALERBA

Lecturer in Gene therapy, Gene Medicine Laboratory for Rare Diseases –

Malerba Research Group, Department of Biological Sciences Royal Holloway, University of London

DR PETER DAVIS

Chair

British Paediatric Surveillance Unit Scientific Committee

JOSIE GODFREY

Co-Founder and CEO

Realise Advocacy

LINDSAY BIRRELL

Co-CEO

Realise Advocacy

Alexander Natz

Secretary General

EUCOPE

Carole Scrafton

Director & Co-Founder,

Flutters and Strutters

Cpt. Luke Rosen

Founder

Rescue7: Firefighters for Patients, and KIF1A.ORG.

Dr Usman Khan

Chair

Motor Neurone Disease (MND) Association

Bob Stevens

Group CEO, MPS Society, Vice Chair

LSD Collaborative

Dr Pooja Takhar

Joint Chief Executive

Tuberous Sclerosis Association

Daniel O’Connor

Director, Regulatory Policy and Early Access

ABPI

Francis Pang

SVP Global Market Access and Geographic Expansion

Orchard Therapeutics

Dr. Rüdiger Schulze

Vice President and General Manager

DACH, Ultragenyx

Robert Mitchell-Thain

CEO

PBC Foundation

Anthony Hall

Co-Founder, Member of Board & Scientific Advisor

Beacon for Rare Diseases

Stefano Benvenuti

Head of Public Affairs and Market Access

Fondazione Telethon

Anna Kole

Global Patient Engagement Lead - MG

UCB

Enrico Piccinini

Head of Europe & International, Rare Diseases

Chiesi Group

Flaminia Macchia

Head, Global Rare Disease Policy

AstraZeneca

Manel Cascallo

General Director

Theriva Biologics Inc

Dr Lucy McKay

Chief Executive Officer

Medics4RareDiseases

Alicia Granados

Global Head Scientific Advocacy & Insights, Rare Diseases

Sanofi

Jennifer Schranz

SVP, Global Head of Rare Diseases

Ipsen

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

SENIOR REPRESENTATIVE

Awaiting for Photo & Bio

Available Shortly

Schedule

Content Rich Program Agenda!  Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

LANDSCAPE OVERVIEW & CURRENT TRENDS

  • Addressing the potential gap in the framework and policy recommendations which support the broad range of people experiencing rare conditions.
  • Strategies for more efficient ways of utilising data for earlier detection and diagnosis of rare diseases
  • Ensuring equity in access to specialised care and innovative treatments.
  • Improving the delivery of clinical research and communication

Moderator:

Panellists:

  • Progress update on the actions set out in previous plans
  • New actions included in the Rare Disease Action Plan for England from 2024
  • Ensuring the plan delivers for people affected by rare conditions
  • Disrupt encourages groundbreaking solutions that fill unmet medical needs.
  • Adopt focuses on strategies to ensure market acceptance through regulatory approvals and commercialization.
  • Collaborate highlights building partnerships across academia, industry, and regulators.
  • Manage emphasizes effective leadership and risk management.
  • Adapt stresses flexibility in dynamic regulatory and market environments.
  • Resource centers on optimizing financial, human, and technological resources.

Dr James Levine, President, Fondation Ipsen

  • The European Parliament is currently reviewing the Pharmaceutical Package, which will potentially be voted on in April – this new text will outline the incentive and regulatory ecosystem for OMP developers. This will be a major milestone in the legislative review.
  • The outcomes of these discussions will shape the landscape for OMP developers in the EU for the next 20 years.
  • Reflect on the changes taking place outside the scope of the legislative framework, including the role of PPP and ERNs
  • Practical challenges in conducting orphan drug clinical trials
  • Technical aspects of clinical trial design for rare diseases
  • Analytical and statistical considerations for clinical trial designs
  • Recommendations for improving the clinical trial design of rare diseases
  • This presentation will focus on the role of RWD in natural history and patient registries.
  • How data can be utilized to help inform study design
  • The use of RWD as an external control and to find eligible patients for trials
  • Using RWD with prior clinical trial data to better understand patient outcomes.

Dr. Femida Gwadry-Sridhar, Founder and CEO, Pulse infoframe Inc.

RESEARCH & DEVELOPMENT

  • How to accelerate drug repositioning?
  • Preclinical models and drug testing
  • Fast-tracked drug access for patients

Prof Guillaume Canaud, Translational Medicine and Targeted Therapies Unit, Necker Enfants Malades

  • Overview of the current trends and recent advancements in NGS technology
  • NGS applications in research and diagnostics
  • Challenges encountered and future directions of NGS technology
  • Different types of nucleotide-based therapeutics?
  • What are the advantages of nucleic acid therapies
  • Addressing the challenges with the safety and efficacy of these technologies in clinical practice
  • Accelerating nucleotide-based therapeutic development through collaborations
  • Muscular dystrophy as paradigm for orphan drug development
  • Most promising gene therapies strategies for the treatment of muscular dystrophy
  • Future perspectives; orphan drugs in the pipeline

Alberto Malerba, Gene Medicine Laboratory for Rare Diseases, Royal Holloway, University of London

  • Role of RWD/E in orphan disease drug development
  • Pitfalls in the use of RWD/E in orphan drug development
  • Repurposing and RWD/E

Surabhi Verma, Chief Medical Officer, Leadiant Biosciences

  • Remarkable advancements in rare disease research
  • Addressing obstacles in development of new treatments and access to trials
  • Significant challenges faced by orphan drug developer
  • Key initiatives that can guide collaborative approaches and innovative strategies to accelerate progress in the rare-disease field.
  • Drug repurposing for rare disease

CHALLENGES AND OPPORTUNITIES

  • Demonstrating the unique challenges of developing a drug for rare diseases.
  • Ways that patients can be involved in designing patient-centered clinical trials
  • Challenges to patient engagement in rare disease research such as operational considerations
  • With focus on the need for collaboration in this space

Moderator:

Panellist:

Dr Pooja Takhar, Joint Chief Executive, Tuberous Sclerosis Association

Daniel O’Connor, Director, Regulatory Policy and Early Access, ABPI

  • There is currently no global agreement on the impact and widespread application of advances in molecular sciences and pathology on the definition of a rare condition
  • Defining rare conditions in the era of personalized medicine includes subsetting of common conditions, sub- setting of rare conditions, individualized treatment options and shared molecular entity conditions.
  • A broader consensus view of what rare means will help maximize the impact of technological advances in therapeutic development programmes

Daniel O’Connor, Director, Regulatory Policy and Early Access, ABPI

  • Define precision medicine and highlight current developments
  • Present an overview of disease populations and sub-populations – both generally and from a regulatory perspective
  • Present case study of Tofersen and MND which highlights impact of appropriate sub-population identification
  • Talk about the policy ask for disease subpopulations
  • Draw more general conclusions with regard to precision medicine and patients

Usman Khan, Chair, Motor Neurone Disease (MND) Association

  • Rare Disease Epidemiology
  • Brief history of Rare Disease recognition
  • A brief review of the development of Genomics
  • The role, importance and benefits of Rare Disease surveillance

Dr Peter Davis, Chair, British Paediatric Surveillance Unit Scientific Committee, Bristol Royal Hospital for Children

  • Innovative application of mRNA therapy for treating Alkaptonuria (AKU)
  • He will discuss the challenges and successes in doing so in pre-clinical models and plans for the future
  • Broader implications of mRNA therapy in the context of rare diseases, expanding the research beyond AKU to include other conditions like Phenylketonuria and Hereditary Tyrosinemia Type 1
  • The presentation aims to engage stakeholders in understanding the potential of mRNA therapeutics to transform treatment paradigms for rare genetic diseases.

Nick Sireau, CEO and Chair of Trustees, AKU Society

  • Establishing Trust and partnership
  • Using 3rd party agencies as a networking, capacity and bridge building partners
  • Building joint successful advocacy campaigns
  • Exploring ethical issues and barriers in joint working
  • What does best practice look like now and in the future.
  • The number one reason patients don’t participate in clinical trials is because of the burden of travel. We can solve that problem.
  • Patient advocates spend too much time away from their family to fundraise. We can solve that problem.

Luke Rosen, CEO of Rescue7: Firefighters for Patients

ACCESS & COLLABORATION

  • This session will examine how we can all leverage this resolution with and within our health systems to make the patient voice count more, count better, and count more sustainably.

Amanda Bok, Chief Strategy Officer, The Synergist

  • Bullet points to follow

Lindsay Randall, Founder, CEO, Mother, Arthur’s Quest

  • Why is patient advocacy beneficial to research?
  • Understanding of elements contributing to meaningful ways of involving patients in research
  • Advantages of involving patients early in research
  • What else needs to be done?

Carole Scrafton, Director & Co-Founder, Flutters and Strutters

  • Aligning with payers and health policymakers around the rare disease policy agenda.
  • Leveraging advanced data analytics to support clinical evidence
  • Fully engaging patient and caregiver communities
  • Creating innovative approaches to funding and contracting
  • Sustainable model addressing both affordability and access

Moderator:


Panellists:

  • Strengthening health systems around the world and accelerating pathways to diagnosis including EU- sponsored international initiatives
  • How can the work from the public and private sector help in accelerating research and raise awareness in rare diseases?
  • How innovation, research and investments are key to accelerate the development of treatments?
  • How the next Commission and Parliament can support the future of rare disease treatment?
  • Stakeholders to address the rare diseases’ ecosystem gaps to collaboratively build a sustainable roadmap for better health and a brighter future for the patients suffering from rare diseases.

Moderator:


Panellists:

Co-located with the EAP Congress 2025 EU

Newsletter Sign Up

No Spam – You will only receive relevant information on Orphan Drugs & Rare Diseases, and event updates

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
Salvador Berrios
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
Thomas Martin
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
Adriana E. Manzi
PhD, Managing Director, Atheln, Inc

Previous events

Book Your Place Now! 

Register To Attend Now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available. 

Location

Scroll to Top